主持项目

1.   国家重点研发计划，2020YFE0203000，克隆性造血相关疾病的防控与机制研究，2021.05-2024.04

2.   国家自然科学基金优秀青年科学基金项目，81922002，造血干细胞的生理与病理调控机制，2020.01-2022.12

3.   国家自然科学基金面上项目，81870086，单细胞尺度解析白血病下造血干/祖细胞及其微环境的变化规律及机制，2019.01-2022.12

4.   国家自然科学基金青年科学基金项目，81400077，Egr3调控造血干细胞功能的机制研究，2015.01-2017.12

5.   2019年天津市杰出青年科学基金

6.   2018年首批天津市“青年医学新锐”

7.   2018年第三批天津市“青年拔尖人才支持计划”

8.   中国医学科学院医学与健康科技创新工程，细胞异质性的表观遗传调控机理，2017.01-2020.12，子课题负责人

参加项目

1.   国家自然科学基金委员会中以合作项目，81861148029，剪接体突变和骨髓微环境衰老在急性髓系白血病早期演变中的作用，2018.10-2021.09

2.   国家自然科学基金重点项目，81730006，白血病重塑微环境及其对正常造血的影响机制，2018.01-2022.12

3.   2017年国家重点研发计划，2017YFA0103400，中胚层来源组织干细胞的谱系层级、发育调控及制备策略，2017.07-2021.12

4.   2016年国家重点研发计划，2016ZY05002341，造血干细胞发育、维持与再生的调控机制，2016.01-2020.12

5.   国家自然科学基金重点项目，81430004，急性髓系白血病细胞干性的调控机制及干预策略，2015.01-2019.12

6.   国家自然科学基金重大项目，81090410，白血病状态下正常造血干/祖细胞的生物学行为及其调控机制，2011.01-2014.12

代表性文章

1.     Wang FJ. #, He J.#, Liu S.#, Gao A., Yang L., Sun G., Ding W., Li C., Wang F., Wang X., Zhu P., Hao S., Ma Y.*, Cheng H.*, Yu J.*, Cheng T*. Comprehensive RNA Editome Reveals Edited Azin1 as A DDX1 Partner to Facilitate Hematopoietic Stem Cell Differentiation. Blood. 2021 (in revision)

2.     Yuan S., Sun G., Zhang Y., Dong F., Cheng H.*, Cheng T*. Understanding the ‘SMART’ features of hematopoietic stem cells and beyond. Science China Life sciences. 2021

3.     Huang D.#, Sun G.#, Hao X.#, He X.#, Zheng Z., Chen C.,Yu Z., Xie L., Ma S., Liu L., Zhou B., Cheng H.*, Zheng J.*, and Cheng T*. ANGPTL2-containingsmall extracellular vesicles from vascular endothelial cells accelerate leukemia progression. The Journal of Clinical Investigation. 2021;131(1).

4.     Wang T.#, Xia C.#, Weng Q., Wang K., Dong Y., Hao S., Dong F., Liu X., Liu L., Geng Y., Guan Y., Du J., Cheng T., Cheng H.*, Wang J*. Loss of Nupr1 promotes engraftment by tuningthe quiescence threshold of hematopoietic stem cell repository via regulatingp53-checkpoint pathway. Haematologica. 2020.

5.      Zhang C.#, Xu Z.#, Yang S.#, Sun G.#, Jia L., Zheng Z., Gu Q., Tao W.*, Cheng T.*, Li C.* and Cheng H.*. tagHi-C reveals 3D chromatin architecture dynamics during hematopoiesis. Cell Reports. 2020;32(13)

6.      Dong F., Cheng H.*, Ema H.*, Cheng T*. Probingthe fate of transplanted hematopoietic stem cells: is the combinational approach "FIT" for purpose? Science China Life sciences. 2020;63(11):1755-8.

7.      Dong F.#, Hao S.#, Zhang S.#, Zhu C.#, Cheng H.#, et al. Differentiation of transplanted haematopoietic stem cells tracked bysingle-cell transcriptomic analysis. Nature Cell Biology. 2020;22(6):630-9.

8.      Xia C.#, Wang T.#, Cheng H.#, et al. Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia. 2020;34(9):2375-83.

9.      Ma S.#, Sun G.#, Yang S., Ju Z.*, Cheng T.*, Cheng H.*. Effects of telomere length on leukemogenesis. Science China Life sciences. 2020;63(2):308-11

10.   Wang Y.#, Lu T.#, Sun G.#, Zheng Y.#, Yang S., Zhang H., Hao S., Liu Y., Ma S., Zhang H., Ru Y., Gao S., Yen K.*, Cheng H.*, Cheng T.*. Targeting of apoptosis gene loci by reprogramming factors leads toselective eradication of leukemia cells. Nature communications. 2019;10(1):5594.

11.   Gao A.#, Gong Y.#, Zhu C., Yang W., Li Q., Zhao M., Ma S., Li J., Hao S.*, Cheng H.*, Cheng T*. Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. Haematologica. 2019;104(10):1950-61.

12.   Cheng H.#*, Zheng Z.#, Cheng T.*. New paradigms on hematopoietic stem cell differentiation. Protein & cell. 2019;11(1):34-44.

13.   Cheng H.#*, Sun G.#, Cheng T*. Hematopoiesis and microenvironment in hematological malignancies. Cell Regeneration (Lond). 2018;7:22-26

14.   Gong, Y., Zhao,M., Yang, W., Gao, A., Yin, X., Hu, L., Wang, X., Xu, J., Hao, S., Cheng, T*. and Cheng, H*. Megakaryocyte-derived excessive TGFbeta1 inhibits proliferationof normal hematopoietic stem cells in acute myeloid leukemia. Experimental Hematology. 2018;60:40-46

15.   Cheng H., Liu Y., Jia Q., Ma S., Yuan W., Jia H., and Cheng T*. Novel regulators in hematopoietic stem cells can be revealed by a functional approach under leukemic condition. Leukemia. 2016;30:2074-77.

16.   Cheng H., and Cheng T*. 'Waterloo': when normal blood cells meet leukemia. Current opinion in hematology. 2016;23:304-10.

17.   Cheng H.#, Hao S#., Liu Y., Pang Y., Ma S., Dong F., Xu J.,Zheng G., Li S., Yuan W., and Cheng T*. Leukemic marrow infiltration reveals anovel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood. 2015;126:1302-13.

18.   Liu Y#., Cheng H.#, Gao S., Lu X., He F., Hu L., Hou D., Zou Z., Li Y., Zhang H., Xu J., Kang L., Wang Q., Yuan W., and Cheng T*. Reprogramming of MLL-AF9 leukemia cells intopluripotent stem cells. Leukemia. 2014;28:1071-80.

中国生理学会青年委员